CY1119567T1 - Θεραπευτικα πεπτιδια - Google Patents
Θεραπευτικα πεπτιδιαInfo
- Publication number
- CY1119567T1 CY1119567T1 CY20171100467T CY171100467T CY1119567T1 CY 1119567 T1 CY1119567 T1 CY 1119567T1 CY 20171100467 T CY20171100467 T CY 20171100467T CY 171100467 T CY171100467 T CY 171100467T CY 1119567 T1 CY1119567 T1 CY 1119567T1
- Authority
- CY
- Cyprus
- Prior art keywords
- therapeutic peptides
- peptides
- bind
- complementarity
- domains
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Radiology & Medical Imaging (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Αποκαλύπτονται συνθέσεις που περιλαμβάνουν πεπτίδια που δεσμεύονται ανοσοσυγκεκριμένα σε καθορισμένους εταίρους δέσμευσης, όπου τα πεπτίδια περιλαμβάνουν τουλάχιστον προσδιοριστικές της συμπληρωματικότητας περιοχές που σχετίζονται με τις περιοχές συμπληρωματικότητας που δεσμεύονται στο MICA ανθρώπου ή στην αγγειοποιητίνη-2.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161541921P | 2011-09-30 | 2011-09-30 | |
PCT/US2012/057839 WO2013049517A2 (en) | 2011-09-30 | 2012-09-28 | Therapeutic peptides |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1119567T1 true CY1119567T1 (el) | 2018-03-07 |
Family
ID=47996757
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20171100467T CY1119567T1 (el) | 2011-09-30 | 2017-04-26 | Θεραπευτικα πεπτιδια |
Country Status (29)
Country | Link |
---|---|
US (2) | US9402905B2 (el) |
EP (3) | EP2760471B9 (el) |
JP (2) | JP2014532053A (el) |
KR (2) | KR102017070B1 (el) |
CN (2) | CN107098967A (el) |
AU (1) | AU2012315792B2 (el) |
BR (1) | BR112014007487A2 (el) |
CA (1) | CA2850542A1 (el) |
CL (1) | CL2014000786A1 (el) |
CO (1) | CO7020866A2 (el) |
CY (1) | CY1119567T1 (el) |
DK (1) | DK2760471T3 (el) |
EA (1) | EA201490644A1 (el) |
ES (3) | ES2619707T3 (el) |
HK (2) | HK1199835A1 (el) |
HR (1) | HRP20170494T1 (el) |
HU (1) | HUE034044T2 (el) |
IL (1) | IL231604B (el) |
LT (1) | LT2760471T (el) |
MX (1) | MX355877B (el) |
NZ (2) | NZ721184A (el) |
PE (1) | PE20142361A1 (el) |
PL (1) | PL2760471T3 (el) |
PT (1) | PT2760471T (el) |
RS (1) | RS55822B1 (el) |
SG (1) | SG11201401104WA (el) |
SI (1) | SI2760471T1 (el) |
TN (1) | TN2014000134A1 (el) |
WO (1) | WO2013049517A2 (el) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2083857A4 (en) * | 2006-09-22 | 2010-03-24 | Dana Farber Cancer Res Inc | METHOD FOR TREATING INTERFERENCE IN CONNECTION WITH MICA |
ES2619707T3 (es) | 2011-09-30 | 2017-06-26 | Dana-Farber Cancer Institute, Inc. | Péptidos terapéuticos |
AU2013218017B2 (en) * | 2012-02-07 | 2017-12-07 | Innate Pharma | MICA binding agents |
BR112015021576A2 (pt) * | 2013-03-15 | 2017-10-10 | Dana Farber Cancer Inst Inc | peptídeos terapêuticos |
CA2906356A1 (en) | 2013-03-15 | 2014-09-18 | Novelogics Biotechnology, Inc. | Antibodies to mica and micb proteins |
WO2015003114A1 (en) * | 2013-07-05 | 2015-01-08 | University Of Washington Through Its Center For Commercialization | Soluble mic neutralizing monoclonal antibody for treating cancer |
CN106029694A (zh) | 2013-12-06 | 2016-10-12 | 达纳-法伯癌症研究院公司 | 治疗性肽 |
CA2939006A1 (en) | 2014-03-14 | 2015-09-17 | Dana-Farber Cancer Institute, Inc. | Vaccine compositions and methods for restoring nkg2d pathway function against cancers |
US20170198054A1 (en) * | 2014-05-21 | 2017-07-13 | Dana-Farber Cancer Institute | Methods for treating cancer with anti bip or anti mica antibodies |
WO2016154585A1 (en) | 2015-03-26 | 2016-09-29 | Charles Sentman | Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using |
NZ742663A (en) | 2015-12-04 | 2023-02-24 | Dana Farber Cancer Inst Inc | Vaccination with mica/b alpha 3 domain for the treatment of cancer |
JP2019517993A (ja) * | 2016-03-15 | 2019-06-27 | イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. | 抗mica抗体 |
US10448746B2 (en) * | 2016-03-15 | 2019-10-22 | Nadia Galloway | Bed sheet with an integrated body positioner |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
WO2018022831A1 (en) * | 2016-07-28 | 2018-02-01 | Musc Foundation For Research Development | Methods and compositions for the treatment of cancer combining an anti-smic antibody and immune checkpoint inhibitors |
CA3040421A1 (en) | 2016-10-19 | 2018-04-26 | Novelogics Biotechnology, Inc. | Antibodies to mica and micb proteins |
CN110267678A (zh) * | 2016-10-29 | 2019-09-20 | 霍夫曼-拉罗奇有限公司 | 抗mic抗体和使用方法 |
US20210101980A1 (en) | 2017-03-31 | 2021-04-08 | Bristol-Myers Squibb Company | Methods of treating tumor |
KR20200064132A (ko) | 2017-10-15 | 2020-06-05 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
MX2020007880A (es) * | 2018-01-25 | 2021-05-14 | Cullinan Mica Corp | Anticuerpos de mica/b y metodos de uso. |
EP3768715A1 (en) | 2018-03-23 | 2021-01-27 | Bristol-Myers Squibb Company | Antibodies against mica and/or micb and uses thereof |
WO2019191676A1 (en) | 2018-03-30 | 2019-10-03 | Bristol-Myers Squibb Company | Methods of treating tumor |
WO2020035345A1 (en) * | 2018-08-14 | 2020-02-20 | Innate Pharma | Treatment of colorectal cancer by a combination of an anti-mica antibody and an anti-nkg2a antibody |
CN113637077B (zh) * | 2021-10-14 | 2021-12-24 | 尚健单抗(北京)生物技术有限公司 | 一种抗mica的抗体及其应用 |
Family Cites Families (115)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
US5981216A (en) | 1985-04-01 | 1999-11-09 | Alusuisse Holdings A.G. | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
EP0351410A1 (en) | 1987-03-18 | 1990-01-24 | 3i RESEARCH EXPLOITATION LIMITED | Complement-binding peptide |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
GB8709290D0 (en) | 1987-04-16 | 1987-05-20 | Secretary Trade Ind Brit | Precision motion slideways |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
ATE135370T1 (de) | 1988-12-22 | 1996-03-15 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
EP0814159B1 (en) | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Transgenic mice capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
CA2507749C (en) | 1991-12-13 | 2010-08-24 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
AU4116793A (en) | 1992-04-24 | 1993-11-29 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
JPH07509137A (ja) | 1992-07-24 | 1995-10-12 | セル ジェネシス,インク. | 異種抗体の生産 |
CA2163345A1 (en) | 1993-06-16 | 1994-12-22 | Susan Adrienne Morgan | Antibodies |
US6091001A (en) | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
EP1709970A1 (en) | 1995-04-27 | 2006-10-11 | Abgenix, Inc. | Human antibodies against EGFR, derived from immunized xenomice |
AUPN568095A0 (en) | 1995-09-27 | 1995-10-26 | Austin Research Institute, The | Anti-Galalpha(1,3)Gal antibody binding peptides |
DE69731289D1 (de) | 1996-03-18 | 2004-11-25 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
EP0937258A2 (en) | 1996-10-29 | 1999-08-25 | Fred Hutchinson Cancer Research Center, Inc. | Cell stress regulated human mhc class i gene |
ATE549918T1 (de) | 1996-12-03 | 2012-04-15 | Amgen Fremont Inc | Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
US5830698A (en) | 1997-03-14 | 1998-11-03 | Idec Pharmaceuticals Corporation | Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same |
AU736549B2 (en) | 1997-05-21 | 2001-08-02 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Method for the production of non-immunogenic proteins |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
ES2292236T3 (es) | 1998-04-02 | 2008-03-01 | Genentech, Inc. | Variantes de anticuerpos y sus fragmentos. |
ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
PL209786B1 (pl) | 1999-01-15 | 2011-10-31 | Genentech Inc | Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
DK2275540T3 (en) | 1999-04-09 | 2016-05-09 | Kyowa Hakko Kirin Co Ltd | Method for controlling the activity of immunologically functional molecule. |
US20090175821A1 (en) | 1999-05-17 | 2009-07-09 | Bridon Dominique P | Modified therapeutic peptides with extended half-lives in vivo |
US6475220B1 (en) | 1999-10-15 | 2002-11-05 | Whiteside Biomechanics, Inc. | Spinal cable system |
CN1406249B (zh) | 2000-02-11 | 2010-06-16 | 默克专利股份有限公司 | 增加基于抗体的融合蛋白的循环半衰期 |
US6725230B2 (en) | 2000-07-18 | 2004-04-20 | Aegis Analytical Corporation | System, method and computer program for assembling process data of multi-database origins using a hierarchical display |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US20040115198A1 (en) | 2001-02-28 | 2004-06-17 | Fred Hutchinson Cancer Research Center | Activation of lymphocyte populations expressing NKG2D using anti-NKG2D antibodies and ligand derivatives |
WO2002068615A2 (en) | 2001-02-28 | 2002-09-06 | Fred Hutchinson Cancer Research Center, Inc. | Activation of lymphocyte populations expressing nkg2d using anti-nkg2d antibodies and ligand derivatives |
US6566208B2 (en) | 2001-07-25 | 2003-05-20 | Chartered Semiconductor Manufacturing Ltd. | Method to form elevated source/drain using poly spacer |
US7084257B2 (en) * | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
EP1443961B1 (en) | 2001-10-25 | 2009-05-06 | Genentech, Inc. | Glycoprotein compositions |
US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
AU2003217912A1 (en) | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
ATE394674T1 (de) | 2002-04-22 | 2008-05-15 | Univ Florida | Funktionalisierte nanopartikel und verwendungsverfahren |
CA2483343A1 (en) * | 2002-04-22 | 2003-10-30 | Fred Hutchinson Cancer Research Center | Soluble mic polypeptides as markers for diagnosis, prognosis and treatment of cancer and autoimmune diseases or conditions |
ES2381617T5 (es) | 2002-08-14 | 2016-02-24 | Macrogenics, Inc. | Anticuerpos específicos frente a FcgammaRIIB y sus procedimientos de uso |
EP2042517B1 (en) | 2002-09-27 | 2012-11-14 | Xencor, Inc. | Optimized FC variants and methods for their generation |
PT1562972E (pt) | 2002-10-15 | 2010-11-10 | Facet Biotech Corp | Alteração de afinidades de ligação ao fcrn ou semi-vidas séricas de anticorpos por mutagénese |
EP1587540B1 (en) | 2003-01-09 | 2021-09-15 | MacroGenics, Inc. | IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME |
US7666417B2 (en) | 2003-04-22 | 2010-02-23 | Fred Hutchinson Cancer Research Center | Methods and compositions for treating autoimmune diseases or conditions |
US20100069614A1 (en) * | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
KR20140142311A (ko) * | 2003-06-27 | 2014-12-11 | 암젠 프레몬트 인코포레이티드 | 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그 용도 |
US7871610B2 (en) * | 2003-08-12 | 2011-01-18 | Dyax Corp. | Antibodies to Tie1 ectodomain |
US8101720B2 (en) | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
DE602005015542D1 (de) | 2004-01-12 | 2009-09-03 | Applied Molecular Evolution | Varianten der fc-region |
US7276585B2 (en) | 2004-03-24 | 2007-10-02 | Xencor, Inc. | Immunoglobulin variants outside the Fc region |
DK1732588T3 (da) * | 2004-04-05 | 2009-10-12 | Univ California | Modulation af NKG2D |
ES2426817T3 (es) | 2004-08-04 | 2013-10-25 | Mentrik Biotech, Llc | Regiones Fc variantes |
MX2007004247A (es) * | 2004-10-19 | 2007-06-12 | Amgen Inc | Agentes de aglutinacion especifica a angiopoyetina-2. |
US7780963B2 (en) | 2004-10-25 | 2010-08-24 | Merck & Co., Inc. | Anti-ADDL antibodies and uses thereof |
CA2595610C (en) * | 2004-12-21 | 2013-03-05 | Astrazeneca Ab | Antibodies directed to angiopoietin-2 and uses thereof |
US20080148432A1 (en) * | 2005-12-21 | 2008-06-19 | Mark Scott Abad | Transgenic plants with enhanced agronomic traits |
LT2397156T (lt) | 2005-06-08 | 2017-02-27 | Dana-Farber Cancer Institute, Inc. | Būdai ir kompozicijos, skirti nuolatinių infekcijų ir vėžio gydymui inhibuojant užprogramuotos ląstelės mirties-1 (pd-1) kelią |
CA2622673C (en) * | 2005-09-21 | 2017-06-27 | Thomas Maier | Sulphonylpyrroles and use thereof as inhibitors of hdac s |
WO2007055926A1 (en) | 2005-11-03 | 2007-05-18 | Fred Hutchinson Cancer Research Center | Negative immunomodulation of immune responses by nkg2d-positive cd4+ cells |
US8248965B2 (en) | 2005-11-03 | 2012-08-21 | Motorola Solutions, Inc. | Method and apparatus regarding use of a service convergence fabric |
TW200730191A (en) * | 2005-12-15 | 2007-08-16 | Astrazeneca Ab | Combinations |
DE102006009847A1 (de) | 2006-03-01 | 2007-09-06 | Sweredjuk, Robert, Dr. | Verfahren von Absorbieren von Schadstoffen und Gerüchen |
MX2009001412A (es) | 2006-08-07 | 2009-04-24 | Harvard College | Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas. |
US20110060120A1 (en) | 2006-09-08 | 2011-03-10 | Obeid Michel Sarkis | Immunogenic treatment of cancer by peptides inducing the plasma membrane exposure of erp57 |
EP2083857A4 (en) | 2006-09-22 | 2010-03-24 | Dana Farber Cancer Res Inc | METHOD FOR TREATING INTERFERENCE IN CONNECTION WITH MICA |
WO2008043018A1 (en) * | 2006-10-04 | 2008-04-10 | Dana-Farber Cancer Institute, Inc. | Tumor immunity |
EP1944611A1 (en) * | 2007-01-11 | 2008-07-16 | Université de la Méditerranée | Biomarker for the medicine and the biology of the reproduction |
CA3011859A1 (en) | 2007-04-23 | 2008-10-30 | Fred Hutchinson Cancer Research Center | Negative immunomodulation of immune responses by erp5 |
AU2008254951A1 (en) * | 2007-05-14 | 2008-11-27 | Biogen Idec Ma Inc. | Single-chain Fc (ScFc) regions, binding polypeptides comprising same, and methods related thereto |
WO2011063336A2 (en) | 2009-11-20 | 2011-05-26 | President And Fellows Of Harvard College | Secondary site of antigen stimulation for therapeutic vaccination |
WO2009102465A2 (en) | 2008-02-13 | 2009-08-20 | President And Fellows Of Harvard College | Continuous cell programming devices |
US9370558B2 (en) | 2008-02-13 | 2016-06-21 | President And Fellows Of Harvard College | Controlled delivery of TLR agonists in structural polymeric devices |
JO2913B1 (en) * | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
US8685393B2 (en) * | 2008-03-24 | 2014-04-01 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment and diagnosis of systemic anthrax infection |
US8182809B1 (en) | 2008-09-08 | 2012-05-22 | University Of Washington | Methods for treating cancer by inhibiting MIC shedding |
US8133979B2 (en) | 2008-12-16 | 2012-03-13 | Hoffmann-La Roche Inc. | Antibodies against human angiopoietin 2 |
US8207497B2 (en) | 2009-05-08 | 2012-06-26 | Ionsense, Inc. | Sampling of confined spaces |
JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
KR101688522B1 (ko) | 2009-12-15 | 2016-12-21 | 삼성전자주식회사 | 안지오포이에틴-2에 특이적으로 결합하는 항체 및 그의 용도 |
US8796420B2 (en) | 2009-12-31 | 2014-08-05 | Avidbiotics Corp. | Non-natural MIC proteins |
KR102116296B1 (ko) * | 2010-02-08 | 2020-05-28 | 리제너론 파마슈티칼스 인코포레이티드 | 일반적인 경쇄 마우스 |
US8753640B2 (en) | 2011-05-31 | 2014-06-17 | University Of Washington Through Its Center For Commercialization | MIC-binding antibodies and methods of use thereof |
CN102911270A (zh) * | 2011-08-05 | 2013-02-06 | 浙江大学 | 一种抑制移植器官慢性排斥反应的抗体的制备及纯化方法 |
ES2619707T3 (es) | 2011-09-30 | 2017-06-26 | Dana-Farber Cancer Institute, Inc. | Péptidos terapéuticos |
AU2013218017B2 (en) * | 2012-02-07 | 2017-12-07 | Innate Pharma | MICA binding agents |
BR112015021576A2 (pt) | 2013-03-15 | 2017-10-10 | Dana Farber Cancer Inst Inc | peptídeos terapêuticos |
CN105051491B (zh) | 2013-03-28 | 2017-07-25 | 本田技研工业株式会社 | 告知***、电子设备、告知方法及程序 |
US9572898B2 (en) | 2013-09-09 | 2017-02-21 | Seton Hall University | Functionalized fluorine containing phthalocyanine molecules |
CN106029694A (zh) | 2013-12-06 | 2016-10-12 | 达纳-法伯癌症研究院公司 | 治疗性肽 |
CA2939006A1 (en) | 2014-03-14 | 2015-09-17 | Dana-Farber Cancer Institute, Inc. | Vaccine compositions and methods for restoring nkg2d pathway function against cancers |
US20170198054A1 (en) | 2014-05-21 | 2017-07-13 | Dana-Farber Cancer Institute | Methods for treating cancer with anti bip or anti mica antibodies |
-
2012
- 2012-09-28 ES ES12835118.6T patent/ES2619707T3/es active Active
- 2012-09-28 AU AU2012315792A patent/AU2012315792B2/en not_active Ceased
- 2012-09-28 PL PL12835118T patent/PL2760471T3/pl unknown
- 2012-09-28 PT PT128351186T patent/PT2760471T/pt unknown
- 2012-09-28 KR KR1020147011604A patent/KR102017070B1/ko active IP Right Grant
- 2012-09-28 SG SG11201401104WA patent/SG11201401104WA/en unknown
- 2012-09-28 RS RS20170344A patent/RS55822B1/sr unknown
- 2012-09-28 CA CA2850542A patent/CA2850542A1/en not_active Abandoned
- 2012-09-28 EP EP12835118.6A patent/EP2760471B9/en active Active
- 2012-09-28 SI SI201230885A patent/SI2760471T1/sl unknown
- 2012-09-28 EP EP17153342.5A patent/EP3210625B1/en active Active
- 2012-09-28 LT LTEP12835118.6T patent/LT2760471T/lt unknown
- 2012-09-28 CN CN201611028760.9A patent/CN107098967A/zh active Pending
- 2012-09-28 PE PE2014000443A patent/PE20142361A1/es not_active Application Discontinuation
- 2012-09-28 WO PCT/US2012/057839 patent/WO2013049517A2/en active Application Filing
- 2012-09-28 KR KR1020197025075A patent/KR102225422B1/ko active IP Right Grant
- 2012-09-28 JP JP2014533375A patent/JP2014532053A/ja active Pending
- 2012-09-28 ES ES17153342T patent/ES2757473T3/es active Active
- 2012-09-28 EA EA201490644A patent/EA201490644A1/ru unknown
- 2012-09-28 DK DK12835118.6T patent/DK2760471T3/en active
- 2012-09-28 BR BR112014007487A patent/BR112014007487A2/pt not_active IP Right Cessation
- 2012-09-28 EP EP19190367.3A patent/EP3628329B1/en active Active
- 2012-09-28 NZ NZ721184A patent/NZ721184A/en not_active IP Right Cessation
- 2012-09-28 HU HUE12835118A patent/HUE034044T2/en unknown
- 2012-09-28 NZ NZ623086A patent/NZ623086A/en not_active IP Right Cessation
- 2012-09-28 ES ES19190367T patent/ES2925654T3/es active Active
- 2012-09-28 MX MX2014003601A patent/MX355877B/es active IP Right Grant
- 2012-09-28 CN CN201280059185.2A patent/CN103958543B/zh not_active Expired - Fee Related
-
2013
- 2013-09-12 US US14/025,573 patent/US9402905B2/en active Active
-
2014
- 2014-03-19 IL IL231604A patent/IL231604B/en not_active IP Right Cessation
- 2014-03-28 TN TNP2014000134A patent/TN2014000134A1/en unknown
- 2014-03-28 CL CL2014000786A patent/CL2014000786A1/es unknown
- 2014-04-22 CO CO14085781A patent/CO7020866A2/es unknown
-
2015
- 2015-01-13 HK HK15100342.8A patent/HK1199835A1/xx not_active IP Right Cessation
-
2016
- 2016-07-15 US US15/211,758 patent/US10793633B2/en active Active
-
2017
- 2017-03-27 HR HRP20170494TT patent/HRP20170494T1/hr unknown
- 2017-04-26 CY CY20171100467T patent/CY1119567T1/el unknown
- 2017-09-22 JP JP2017182107A patent/JP2018048139A/ja active Pending
-
2018
- 2018-02-27 HK HK18102806.0A patent/HK1243427A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1119567T1 (el) | Θεραπευτικα πεπτιδια | |
CY1121517T1 (el) | Μη φουκοζυλιωμενα αντισωματα enanti-fgfr2iiib | |
CY1122278T1 (el) | Αντι il-36r αντισωματα | |
IL276688A (en) | Stable formulations of double variable region immunoglobulin proteins | |
CY1118014T1 (el) | Aνti-il-23 αντισωματα | |
CY1121742T1 (el) | Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων | |
EA201791693A1 (ru) | Гетеродимерные иммуноглобулины | |
MX2015011075A (es) | Peptidos terapeuticos. | |
EA201791485A1 (ru) | Анти-cd47-антитела и их применения | |
MX2021007663A (es) | Molecula de union al antigeno especifico para el tejido objetivo. | |
EA201401254A1 (ru) | Самостабилизирующиеся линкерные конъюгаты | |
EA201992456A2 (ru) | Самостабилизирующиеся линкерные конъюгаты | |
MX366223B (es) | Proteinas vinculantes que comprenden al menos dos dominios de repeticion contra her2. | |
SG10201902924RA (en) | Antibodies that bind ebola glycoprotein and uses thereof | |
UA110370C2 (en) | Conjugates of amatoxin with improved linkages | |
CY1119154T1 (el) | Anti-vla-4 αντισωματα | |
EA201291039A1 (ru) | Антитела, связывающие cd27 человека, и их применение | |
BR112013020259A2 (pt) | tratamento de osteoartrite e dores | |
MX2012013406A (es) | Variantes de union mejoradas anti-albumina serica. | |
UA106900C2 (uk) | Агоністичний dr5-зв'язувальний поліпептид | |
EA201290642A1 (ru) | Соединения и способы | |
NZ700274A (en) | Anti-pdgf-c antibodies | |
DK3254695T3 (da) | Kombinationsterapi, der involverer antistoffer mod claudin 18.2 til behandling af cancer | |
EA201390955A1 (ru) | Слитый белок robo1-fc для применения в лечении гепатокарциномы | |
MX2013002055A (es) | Variantes anti-enlace de albumina de suero mejodas. |